Evaluation of Tolerability, Efficacy and Adherence to Treatment With Wynzora Cream

Not yet recruiting

• Conditions: Psoriasis

• Registration Number: NCT06180473
• Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Brief Summary

The primary objective is to assess with the PPQ questionnaire the patient preference for Wynzora compared with therapy carried out previously with Enstilar spray foam. Secondary objectives Assess satisfaction with the treatment. Assess adherence to therapy. Evaluate the impact of various clinical and demographic factors on treatment adherence. Evaluate the efficacy of Wynzora cream therapy.

Detailed Description

Not available

Study Timeline

• Status Verified: 2023-12
• Study First Submitted: 2023-12-12
• Study First Submitted QC: 2023-12-12
• Last Update Submitted: 2023-12-12
• Study First Posted: 2023-12-22
• Last Update Posted: 2023-12-22
• Study Start: 2024-01-01
• Primary Completion: 2024-03-31
• Study Completion: 2024-06-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Patients older than 18 years of age, of either sex;
• Patients diagnosed with mild-to-moderate psoriasis (PASI and BSA <10) requiring monotherapy topical with Wynzora;
• Patients who have stopped treatment with Enstilar foam for any reason for at least 30 days; and
• Patients whose medical records are accessible and record all demographic parameters, anthropometric and clinical parameters during the treatment period
• Signature of written informed consent;

Exclusion Criteria

• Patients with palmoplantar, inverse, erythrodermic, guttate, and scalp psoriasis.
• Patients who are taking concomitant systemic therapies for psoriasis, such as. cyclosporine, methotrexate, acitretin, phototherapy or biologic therapies.
• Women who are pregnant or planning to become pregnant.
• Patients with disabilities or other motor problems that could complicate self-medication.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
preference of wynzora cream	1 month	Percentage of patients who prefer treatment with Wynzora compared with treatment with Enstilar at week 4 of use; preference for Wynzora will be assessed by considering a score of 3 or higher on question 5 of the PPQ questionnaire.